R&D portfolio Fractalkine project The problem The solution This is how KAND567 works Next step The future Scientific publications Selected scientific publications Fractalkine ⇒ In a study of 4800 myocardial infarction patients, Professor Ioakim Spyridopoulos’ collaborating partner and his research group have shown the potential of the fractalkine blocker KAND567 to prolong life after an acute myocardial infarction ⇒ Pioneering research results for Kancera’s fractalkine blockers may pave the way for new treatment for ovarian cancer PFKFB3 ⇒ An extensive research study shows that Kancera’s candidate drug, the PFKFB3 inhibitor KAND757, effectively kills tumor preparations from rectal cancer patients by selectively blocking metabolism. ⇒ The drug candidate KAND757 makes cancer cells sensitive to platinum drugs, including treatment-resistant cancer cells, while saving normal cells. The study explains the mechanism behind this effect. ⇒ Molecular mechanisms that cause the small molecule KAN0438757 to have a potent antitumor effect in preclinical models. ROR1 ⇒ Laboratory tests show that a combination of ROR and Bcl2 inhibitors effectively kills cells from small cell cancer. ⇒ Kancera’s drug candidate KAND571 has the capacity to break the treatment resistance of leukemia cells. ⇒ A combination of the ROR inhibitor KAN0441571C and the drug venetoclax caused almost complete elimination of cells from the malignant tumor Diffuse Large B-Cell Lymphoma (DLBCL).